NOS2 and pulmonary fibrosis: The dual-target-directed ligand (S)-MRI-1867 (a combined cannabinoid CB1 receptor and iNOS blocker) is considered a promising drug candidate for pulmonary fibrosis associated with Hermansky–Pudlak syndrome [211].